{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:18:43Z","timestamp":1764688723126},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.diagmicrobio.2009.01.017","type":"journal-article","created":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T09:28:43Z","timestamp":1238059723000},"page":"202-212","source":"Crossref","is-referenced-by-count":15,"title":["Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations"],"prefix":"10.1016","volume":"64","author":[{"given":"Douglas J.","family":"Biedenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jac\/dkm015","article-title":"Are \u03b2-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?","volume":"59","author":"Alou","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib2","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.50.5.1762-1767.2006","article-title":"Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil","volume":"50","author":"Alvarez-Sala","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib3","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.diagmicrobio.2006.12.003","article-title":"Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis","volume":"57","author":"Anzueto","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.diagmicrobio.2008.01.015","article-title":"Antimicrobial activity of cefditoren tested against contemporary (2004\u20132006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States","volume":"61","author":"Biedenbach","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib5","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0149-2918(02)80024-8","article-title":"Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections","volume":"24","author":"Bucko","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jac\/dkm228","article-title":"What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model","volume":"60","author":"Canut","year":"2007","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1442-200x.2004.01928.x","article-title":"Antimicrobial susceptibility of respiratory Haemophilus influenzae strains isolated from pediatric respiratory tract infections","volume":"46","author":"Cao","year":"2004","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/dkf076","article-title":"Activity of cefditoren against respiratory pathogens","volume":"50","author":"Clark","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib9","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014seventh edition, M7-A7","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib10","series-title":"Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S18","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1179\/joc.2007.19.3.288","article-title":"Pharmacodynamics of simulated total versus free-drug serum concentrations of a low versus a high protein bound third-generation oral cephalosporin (cefpodoxime versus cefditoren) against Streptococcus pneumoniae","volume":"19","author":"Echeverria","year":"2007","journal-title":"J. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/jac\/dkm209","article-title":"Influence of the \u03b2-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media","volume":"60","author":"Fenoll","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijantimicag.2006.08.046","article-title":"Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones","volume":"29","author":"Fenoll","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/AAC.41.5.1137","article-title":"Interpretive criteria for testing susceptibility of staphylococci to mupirocin","volume":"41","author":"Finlay","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib15","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0149-2918(02)80084-4","article-title":"A comparison of cefditoren pivoxil and amoxicillin\/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study","volume":"24","author":"Fogarty","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1179\/joc.2008.20.2.170","article-title":"Update of the activity of cefditoren and comparator oral \u03b2-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004\u20132006)","volume":"20","author":"Fritsche","year":"2008","journal-title":"J.\u00a0Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jac\/dkn083","article-title":"Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005\u201306: results of the Cefditoren Surveillance Study","volume":"61","author":"Gracia","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijantimicag.2007.10.024","article-title":"Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers","volume":"31","author":"Granizo","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/107662903764736337","article-title":"Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States","volume":"9","author":"Hasegawa","year":"2003","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0732-8893(01)00274-7","article-title":"Cefditoren in vitro activity and spectrum: a review of international studies using reference methods","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib21","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.clinthera.2006.12.010","volume":"28","author":"Jose Granizo","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0732-8893(01)00331-5","article-title":"Activity of cefditoren against \u03b2-lactamase\u2013positive and -negative Haemophilus influenzae and Moraxella catarrhalis","volume":"42","author":"Karlowsky","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0732-8893(01)00304-2","article-title":"In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren","volume":"42","author":"Karlowsky","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/AAC.00960-06","article-title":"Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea","volume":"51","author":"Kim","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2007.05.011","article-title":"In vitro activity of cefditoren against clinical isolates of Escherichia coli from a Korean hospital","volume":"30","author":"Ko","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijantimicag.2006.02.014","article-title":"In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries","volume":"28","author":"Lee","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib27","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/AAC.00736-06","article-title":"Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.46.5.1273-1280.2002","volume":"46","author":"Nagai","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0924-8579(02)00049-3","article-title":"Oral antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates from Japanese children","volume":"20","author":"Nishi","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10156-008-0602-7","article-title":"Five-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis","volume":"14","author":"Ozaki","year":"2008","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib31","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.clinthera.2008.10.001","article-title":"Efficacy of cefditoren pivoxil and amoxicillin\/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial","volume":"30","author":"Poachanukoon","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.diagmicrobio.2008.06.007","article-title":"In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain","volume":"62","author":"Seral","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/jac\/dkm115","article-title":"Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae","volume":"60","author":"Sevillano","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijantimicag.2003.07.018","article-title":"Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project","volume":"23","author":"Soriano","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/joc.2003.15.2.107","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the Cefditoren Surveillance Program","volume":"15","author":"Soriano","year":"2003","journal-title":"J. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1179\/joc.2008.20.5.561","article-title":"Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy","volume":"20","author":"Stefani","year":"2008","journal-title":"J. Chemother. (Florence, Italy)"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib37","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1128\/AAC.32.9.1421","article-title":"In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin","volume":"32","author":"Tamura","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib38","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/AAC.01530-06","volume":"51","author":"Torrico","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib39","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0149-2918(02)80083-2","article-title":"Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study","volume":"24","author":"van Zyl","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijantimicag.2006.10.014","article-title":"In vitro susceptibility of Spanish isolates of Neisseria gonorrhoeae to cefditoren and five other antimicrobial agents","volume":"29","author":"Vazquez","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib41","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2165\/00003495-200464220-00009","article-title":"Cefditoren pivoxil: a review of its use in the treatment of bacterial infections","volume":"64","author":"Wellington","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2009.01.017_bib42","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1128\/AAC.00743-07","article-title":"Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2\u00d7: structural basis for its high antimicrobial activity","volume":"51","author":"Yamada","year":"2007","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T03:05:32Z","timestamp":1558235132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889309000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0732889309000224"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.01.017","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}